The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

### **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

# FORM D

## **Notice of Exempt Offering of Securities**

OMB APPROVAL

OMB Number: 3235-0076
Estimated average burden
hours per response: 4.00

1. Issuer's Identity			
CIK (Filer ID Number)	Previous	None	Entity Type
,	Names		_ ` ` ` `
0001517681	Propage Health Group Corp		X Corporation
Name of Issuer Propanc Biopharma, Inc.	Propanc Health Group Corporation		Limited Partnership
Jurisdiction of Incorporation/Organia	zation		Limited Liability Company
DELAWARE	Lation		General Partnership
Year of Incorporation/Organization			Business Trust
X Over Five Years Ago			Other (Specify)
Within Last Five Years (Specify )	Year)		Cirler (Specify)
H	r car j		
Yet to Be Formed			
2. Principal Place of Business and	Contact Information		
Name of Issuer			
Propanc Biopharma, Inc.			
Street Address 1		Street Address 2	
302, 6 BUTLER STREET	Otata/Danninaa/O	7ID/D- 1 10 1	Dhara Nasaha (1
CAMPEDWELL VIC	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer
CAMBERWELL, VIC	AUSTRALIA	3124	+61-03-9882-0780
3. Related Persons			
Last Name	First Name		Middle Name
Nathanielsz	James		
Street Address 1	Street Address 2		
302, 6 Butler Street	Ot-t-/D		710/04-10-1-
City Camberwell, VIC	State/Province/Cou	untry	ZIP/PostalCode 3124
Relationship: X Executive Officer X	_		3124
Clarification of Response (if Necess			
Chief Executive Officer and Chief Finan	ncial Officer		
Last Name	First Name		Middle Name
Kenyon	Julian		
Street Address 1	Street Address 2		
302, 6 Butler Street	Otata / D	under c	ZID/Doots/Codo
City Camberwell, VIC	State/Province/Cou AUSTRALIA	anuy	ZIP/PostalCode 3124
Relationship: $X$ Executive Officer $X$	_		3124
	_		
Clarification of Response (if Necessary	ary):		
Chief Scientific Officer			
Last Name	First Name		Middle Name
Zelinger	Josef		
Street Address 1	Street Address 2		
302, 6 Butler Street	Otata/Drawings/O-	intn/	ZID/DoctolCodo
City	State/Province/Cou	ariu y	ZIP/PostalCode
Camberwell, VIC	AUSTRALIA		3124

Relationship: Executive Officer X Direct	or Promoter		
Clarification of Response (if Necessary):			
4. Industry Group			
Agriculture Banking & Financial Services  Commercial Banking Insurance Investing Investment Banking Pooled Investment Fund Is the issuer registered as an investment company under the Investment Company Act of 1940?  Yes No Other Banking & Financial Services Business Services Energy Coal Mining Electric Utilities Energy Conservation Environmental Services Oil & Gas Other Energy	Health Care  Biotechnology  Health Insurance  Hospitals & Physicians  Pharmaceuticals  Other Health Care  Manufacturing  Real Estate  Commercial  Construction  REITS & Finance  Residential  Other Real Estate	Restaurants Technology Computers Telecommunications Other Technology Travel Airlines & Airports Lodging & Conventions Tourism & Travel Services Other Travel Other	
5. Issuer Size			
Revenue Range OR  No Revenues  \$1 - \$1,000,000  \$1,000,001 - \$5,000,000  \$5,000,001 - \$25,000,000  \$25,000,001 - \$100,000,000  Over \$100,000,000  X Decline to Disclose  Not Applicable  6. Federal Exemption(s) and Exclusion(s)	No Aggregate   \$1 - \$5,000,00   \$5,000,001 - \$   \$25,000,001 - \$   \$50,000,001 - \$   Over \$100,00   Decline to Dis   Not Applicable   Not Applicable   S) Claimed (select all that applicable   S) Claimed (select all that applicable   S)	\$25,000,000 - \$50,000,000 - \$100,000,000 00,000 sclose le	
Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(i) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii) X Rule 506(b) Rule 506(c) Securities Act Section 4(a)(5)	Investment Section 3(	Section 3(c)(10)  (c)(3)  Section 3(c)(11)  (c)(4)  Section 3(c)(12)  (c)(5)  Section 3(c)(13)  (c)(6)  Section 3(c)(14)	

7. Type of Filing						
X New Notice Date of First Sale 2023-08-23 First Sale Yet to Occur						
Amendment						
9. Direction of Offician						
8. Duration of Offering						
Does the Issuer intend this offering to last more than one year? Yes X No						
9. Type(s) of Securities Offered (select all that apply)						
Equity	Pooled Investment Fund Interests					
X Debt	Tenant-in-Common Securities					
X Option, Warrant or Other Right to Acquire Another Security	Mineral Property Securities					
X Security to be Acquired Upon Exercise of Option, Warrant or Other R Acquire Security	ight to Other (describe)					
10. Business Combination Transaction						
Is this offering being made in connection with a business combination to or exchange offer?	ansaction, such as a merger, acquisition $Yes X$ No					
Clarification of Response (if Necessary):						
11. Minimum Investment						
Minimum investment accepted from any outside investor \$72,500 USD						
12. Sales Compensation						
Recipient	Recipient CRD Number X None					
(Associated) Broker or Dealer X None	(Associated) Broker or Dealer CRD Number X None					
Street Address 1	Street Address 2					
City	State/Province/Country ZIP/Postal Code					
State(s) of Solicitation (select all that apply) Check "All States" or check individual States	Foreign/non-US					
13. Offering and Sales Amounts						
Total Offering Amount \$72,500 USD or Indefinite						
Total Amount Sold \$72,500 USD						
Total Remaining to be Sold \$0 USD or Indefinite						
Clarification of Response (if Necessary):						
14. Investors						
Select if securities in the offering have been or may be sold to perso such non-accredited investors who already have invested in the offe	ns who do not qualify as accredited investors, and enter the number of ring.					
Regardless of whether securities in the offering have been or may be total number of investors who already have invested in the offering:	e sold to persons who do not qualify as accredited investors, enter the					
15. Sales Commissions & Finder's Fees Expenses						
Provide separately the amounts of sales commissions and finders fees echeck the box next to the amount.	expenses, if any. If the amount of an expenditure is not known, provide an estimate and					
Sales Commissions \$0 USD Estimate						
Finders' Fees \$0 USD Estimate						
Clarification of Response (if Necessary):						
16. Use of Proceeds						
	or is proposed to be used for payments to any of the persons required to be named as the amount is unknown, provide an estimate and check the box next to the amount.					
\$0 USD Estimate						

Clarification of Response (if Necessary):

### Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

#### Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the
  accordance with applicable law, the information furnished to offerees.\*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Propanc Biopharma, Inc.	/s/ James Nathanielsz	James Nathanielsz	Chief Executive Officer and Chief Financial Officer	2023-08-31

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

\* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.